Growing recognition of the role for rare missense substitutions in breast cancer susceptibility

Biomarkers in Medicine

Volumn 8, Issue 4, 2014, Pages 589-603

  Tavtigian, Sean V ^a   Chenevix Trench, Georgia ^b  

^a UNIVERSITY OF UTAH   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

ATM; BRCA1; BRCA2; breast cancer; CHEK2; genetic susceptibility; homologous recombination repair; missense substitution; rare variant; unclassified variant

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; BRCA1 PROTEIN; BRIP1 PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; RNA HELICASE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ATTRIBUTABLE RISK; BREAST CANCER; BRIP1 GENE; CANCER SUSCEPTIBILITY; CHEK2 GENE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PALB2 GENE; PROTEIN MODIFICATION; RECOMBINATION REPAIR; REVIEW; TP53 GENE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; DISEASE PREDISPOSITION; FEMALE; GENETICS; METABOLISM; PATHOLOGY;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; BREAST NEOPLASMS; CHECKPOINT KINASE 2; DISEASE SUSCEPTIBILITY; DNA-BINDING PROTEINS; FEMALE; HUMANS; MUTATION, MISSENSE; NUCLEAR PROTEINS; RNA HELICASES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84899789619     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.143     Document Type: Review

References (103)

1. Broca P. Traite des Tumeurs. P. Asselin, Paris, France (1866).
2. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000).
3. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. Natl Cancer Inst. 86(21), 1600-1608 (1994).
4. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 1(3), e65 (2004).
5. Kerber RA, O'Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 103(9), 1906-1915 (2005).
6. Genetic susceptibility. In: World Cancer Report 2008. Boyle P, Levin B (Eds). IARC Press, Lyon, France, 183-184 (2008).
7. Hall JM, Lee MK, Newman B et al. Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 250(4988), 1684-1689 (1990).
8. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66-71 (1994).
9. Castilla LH, Couch FJ, Erdos MR et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat. Genet. 8(4), 387-391 (1994).
10. Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet. 8(4), 392-398 (1994).
11. Friedman LS, Ostermeyer EA, Szabo CI et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 8(4), 399-404 (1994).
12. Plon SE, Eccles DM, Easton D et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29(11), 1282-1291 (2008).
13. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559), 789-792 (1995).
14. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12(3), 333-337 (1996).
15. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75(4), 535-544 (2004).
16. Neuhausen SL, Ostrander EA. Mutation testing of earlyonset breast cancer genes BRCA1 and BRCA2. Genet. Test. 1(2), 75-83 (1997).
17. InterPro: protein sequence analysis &classification. www.ebi.ac.uk/interpro
18. UniProt. www.uniprot.org
19. NCBI. Conserved Domains and Protein Classification. www.ncbi.nlm.nih.gov/ Structure/cdd/cdd.shtml
20. Alignments - Align GVGD. http://agvgd.iarc.fr/alignments.php
21. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31, 961-967 (2010).
22. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol. 11, 196-207 (2010).
23. Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol. Cell Biol. 33, 387-395 (2013).
24. NHGRI. Breast Cancer Information Core. http://research.nhgri.nih.gov/bic
25. Spurdle AB. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Curr. Opin Genet. Dev. 20(3), 315-323 (2010).
26. Lindor NM, Guidugli L, Wang X et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum. Mutat. 33(1), 8-21 (2012).
27. Vallee MP, Francy TC, Judkins MK et al. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum. Mutat. 33(1), 22-28 (2012).
28. Easton DF, Deffenbaugh AM, Pruss D et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet. 81(5), 873-883 (2007).
29. Zuckerkandl E, Pauling L. Molecules as documents of evolutionary history. J. Theor. Biol. 8(2), 357-366 (1965).
30. Jukes TH, King JL. Deleterious mutations and neutral substitutions. Nature 231(5298), 114-115 (1971).
31. Szabo CI, Wagner LA, Francisco LV et al. Human, canine and murine BRCA1 genes: sequence comparison among species. Hum. Mol. Genet. 5(9), 1289-1298 (1996).
32. Abkevich V, Zharkikh A, Deffenbaugh AM et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J. Med. Genet. 41(7), 492-507 (2004).
33. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum. Mutat. 29(11), 1342-1354 (2008).
34. Tavtigian SV, Samollow PB, de Silva D, Thomas A. An analysis of unclassified missense substitutions in human BRCA1. Fam. Cancer 5(1), 77-88 (2006).
35. Align GVGD. http://agvgd.iarc.fr/alignments.php
36. SIFT. http://sift.jcvi.org
37. PolyPhen-2: prediction of functional effects of human nsSNPs. http://genetics.bwh.harvard.edu/pph2
38. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 11(5), 863-874 (2001).
39. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248-249 (2010).
40. Spurdle AB, Healey S, Devereau A et al. ENIGMA - evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum. Mutat. 33(1), 2-7 (2012).
41. Tinat J, Bougeard G, Baert-Desurmont S et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J. Clin. Oncol. 27(26), e108-e109; author reply e110 (2009).
42. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985), 1233-1238 (1990).
43. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348(6303), 747-749 (1990).
44. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17(1), 43-52 (1979).
45. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312(5995), 649-651 (1984).
46. Jenkins JR, Rudge K, Currie GA. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312(5995), 651-654 (1984).
47. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312(5995), 646-649 (1984).
48. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57(7), 1083-1093 (1989).
49. Levine AJ. The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp. 20, 221-30 (1989).
50. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat. 25(1), 6-17 (2005).
51. Hainaut P, Soussi T, Shomer B et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25(1), 151-157 (1997).
52. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118(5), 1387-1396 (2012).
53. Tavtigian SV, Hashibe M, Thomas A. Tests of association for rare variants: case control mutation screening. Nat. Rev. Genet. 12(3), 224 (2011).
54. Le Calvez-Kelm F, Lesueur F, Damiola F et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutationscreening study. Breast Cancer Res. 13(1), R6 (2011).
55. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316(21), 1289-1294 (1987).
56. FitzGerald MG, Bean JM, Hegde SR et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet. 15(3), 307-310 (1997).
57. Tavtigian SV, Oefner PJ, Babikyan D et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am. J. Hum. Genet. 85(4), 427-446 (2009).
58. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38(8), 873-875 (2006).
59. Bernstein JL, Haile RW, Stovall M et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J. Natl Cancer Inst. 102(7), 475-483 (2010).
60. Goldgar DE, Healey S, Dowty JG et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 13(4), R73 (2011).
61. Stankovic T, Kidd AM, Sutcliffe A et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 62(2), 334-345 (1998).
62. Waddell N, Jonnalagadda J, Marsh A et al. Characterization of the breast cancer associated ATM 7271TG (V2424G) mutation by gene expression profiling. Genes Chromosomes Cancer 45(12), 1169-1181 (2006).
63. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282(5395), 1893-1897 (1998).
64. Chaturvedi P, Eng WK, Zhu Y et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18(28), 4047-4054 (1999).
65. Weinert TA, Kiser GL, Hartwell LH. Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes Dev. 8(6), 652-665 (1994).
66. Allen JB, Zhou Z, Siede W, Friedberg EC, Elledge SJ. The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev. 8(20), 2401-2415 (1994).
67. Bell DW, Varley JM, Szydlo TE et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286(5449), 2528-2531 (1999).
68. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2 (*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31(1), 55-59 (2002).
69. CHEK2 Breast Cancer Case-Control Consortium. CHEK21100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet. 74(6), 1175-1182 (2004).
70. Kilpivaara O, Vahteristo P, Falck J et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer 111(4), 543-547 (2004).
71. Cybulski C, Gorski B, Huzarski T et al. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75(6), 1131-1135 (2004).
72. Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Curr. Opin Genet. Dev. 20(3), 268-276 (2010).
73. Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes - risk and response. J. Mammary Gland Biol. Neoplasia 16(1), 3-15 (2011).
74. Desrichard A, Bidet Y, Uhrhammer N, Bignon YJ. CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res. 13(6), R119 (2011).
75. Xia B, Sheng Q, Nakanishi K et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22(6), 719-729 (2006).
76. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep. 10(9), 990-996 (2009).
77. Zhang F, Bick G, Park JY, Andreassen PR. MDC1 and RNF8 function in a pathway that directs BRCA1- dependent localization of PALB2 required for homologous recombination. J. Cell. Sci. 125(Pt 24), 6049-6057 (2012).
78. Xia B, Dorsman JC, Ameziane N et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39(2), 159-161 (2007).
79. Rahman N, Seal S, Thompson D et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39(2), 165-167 (2007).
80. Erkko H, Xia B, Nikkila J et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133), 316-319 (2007).
81. Tischkowitz M, Xia B, Sabbaghian N et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc. Natl Acad. Sci. USA 104(16), 6788-6793 (2007).
82. Tischkowitz M, Capanu M, Sabbaghian N et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum. Mutat. 33(4), 674-680 (2012).
83. Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38(11), 1239-1241 (2006).
84. Thompson ER, Doyle MA, Ryland GL et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet. 8(9), e1002894 (2012).
85. Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV et al. High prevalence and breast cancer predisposing role of the BLM c.1642 CT (Q548X) mutation in Russia. Int. J. Cancer 130(12), 2867-2873 (2012).
86. Guilford PJ, Hopkins JB, Grady WM et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum. Mutat. 14(3), 249-255 (1999).
87. Schumacher V, Vogel T, Leube B et al. STK11 genotyping and cancer risk in Peutz-Jeghers syndrome. J. Med. Genet. 42(5), 428-435 (2005).
88. Bartkova J, Tommiska J, Oplustilova L et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancerpredisposing gene. Mol. Oncol. 2, 296-316 (2008).
89. Heikkinen K, Karppinen SM, Soini Y et al. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J. Med. Genet. 40, e131 (2003).
90. Heikkinen K, Rapakko K, Karppinen SM et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27, 1593-1599 (2006).
91. di Masi A, Antoccia A. NBS1 heterozygosity and cancer risk. Curr. Genomics 9, 275-281 (2008).
92. Zhang ZH, Yang LS, Huang F et al. Current evidence on the relationship between two polymorphisms in the NBS1 gene and breast cancer risk: a meta-analysis. Asian Pac. J. Cancer Prev. 13, 5375-5379 (2012).
93. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 18(2), 400-407 (2012).
94. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42(5), 410-414 (2010).
95. Osorio A, Endt D, Fernandez F et al. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum. Mol. Genet. 21(13), 2889-2898 (2012).
96. Park DJ, Lesueur F, Nguyen-Dumont T et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am. J. Hum. Genet. 90(4), 734-739 (2012).
97. Karppinen SM, Barkardottir RB, Backenhorn K et al. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J. Med. Genet. 43(11), 856-862 (2006).
98. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21(12), 2397-2406 (2003).
99. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J. Clin. Oncol. 28(5), 893-901 (2010).
100. Le Calvez-Kelm F, Oliver J, Damiola F et al.t al. RAD51 and Breast Cancer Susceptibility: No Evidence for Rare Variant Association in the Breast Cancer Family Registry Study. PLoS ONE 7(12), e52374 (2012).
101. Mitui M, Nahas SA, Du LT et al. Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum. Mutat. 30(1), 12-21 (2009).
102. Roeb W, Higgins J, King MC. Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum. Mol. Genet. 21(12), 2738-2744 (2012).
103. Kato S, Han SY, Liu W et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA 100(14), 8424-8429 (2003).